Company Encyclopedia
View More
name
Context Therapeutics
CNTX.US
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.
4.654 T
CNTX.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Context Therapeutics Inc. (NASDAQ:CNTX) Given Consensus Recommendation of "Moderate Buy" by Brokerages

    Context Therapeutics Inc. (NASDAQ:CNTX) has received a "Moderate Buy" consensus rating from nine research firms. The average 12-month target price is $5.40. Analysts have varied ratings: one "sell," seven "buy," and one "strong buy." Recent reports include Cantor Fitzgerald's "overweight" rating and HC Wainwright's price objective increase to $5.00. The stock opened at $1.12, with a market cap of $102.91 million. Institutional investors hold 14.03% of the stock.

    Market Beat·
    US
    CNTX
    +10.43%
    Market Beat·
    US
    CNTX
    +10.43%

    Buy Rating for Context Therapeutics: Strong Financials and Promising Clinical Developments

    Jason McCarthy from Maxim Group has reiterated a Buy rating for Context Therapeutics, setting a price target of $5.00. This rating is based on the company's strong financial position, with a healthy cash reserve expected to last until 2027, and promising clinical developments, particularly in its bispecific antibody programs. The CTIM-76 trial has shown early signs of antitumor activity. Despite a net loss, the company's stock has seen significant growth, reflecting positive market sentiment in the biotech sector.

    Tip Ranks·
    US
    CNTX
    +10.43%
    Tip Ranks·
    US
    CNTX
    +10.43%

    Context Therapeutics Advances CT-95 and CT-202 Programs Toward Clinical Trials

    Context Therapeutics Inc. announced progress on its CT-95 and CT-202 programs at the 2025 SITC Annual Meeting. CT-95, a bispecific T cell engager, is in a Phase 1 trial with six patients, showing no severe cytokine release syndrome or dose-limiting toxicities. Initial data is expected in mid-2026. CT-202 is advancing towards a first-in-human trial, with regulatory filings anticipated in Q2 2026. Future results for both programs will be presented.

    Reuters·
    US
    CNTX
    +10.43%
    Reuters·
    US
    CNTX
    +10.43%

    Context Therapeutics (NASDAQ:CNTX) Announces Earnings Results

    Context Therapeutics (NASDAQ:CNTX) reported quarterly earnings of ($0.10) per share, missing analysts' estimates of ($0.09) by $0.01. The stock traded up 1.8% to $1.13, with a consensus rating of "Moderate Buy" and an average target price of $5.20. Analysts have mixed ratings, with one Strong Buy, seven Buy, and one Sell. The company focuses on developing treatments for solid tumors, with its lead candidate being CTIM-76, a bispecific antibody for cancer therapy.

    Market Beat·
    US
    CNTX
    +10.43%
    Market Beat·
    US
    CNTX
    +10.43%

    Positive Outlook for Context Therapeutics: Promising Developments in CTIM-76 Study Justify Buy Rating

    William Blair analyst Matt Phipps has maintained a Buy rating on Context Therapeutics (CNTX) stock, citing promising developments in the CTIM-76 study. Preliminary data from the Phase Ia study showed early antitumor activity, particularly in a patient with platinum-resistant ovarian cancer. The study reported no severe cytokine release syndrome or dose-limiting toxicities, indicating a favorable safety profile. Piper Sandler also issued a Buy rating with a $4.00 price target on the same day, reinforcing the positive outlook for the company.

    Tip Ranks·
    US
    CNTX
    +10.43%
    Tip Ranks·
    US
    CNTX
    +10.43%
    © 2025 Longbridge｜Disclaimer